Abstract:Quynh Nguyen, *,1 Kenji Rowel Q Lim, *,1 Toshifumi Yokota, 1,2 1 Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada; 2 The Friends of Garrett Cumming Research & Muscular Dystrophy Canada, HM Toupin Neurological Science Research Chair, Edmonton, AB, Canada *These authors contributed equally to this work Congenital muscular dystrophy (CMD) is a class of severe early-onset muscular dystrophies affecting skeletal/cardiac muscles as well as the central nervous system (CNS). Laminin-α2 chain-deficient congenital muscular dystrophy (LAMA2 MD), also known as merosin-deficient congenital muscular dystrophy type 1A (MDC1A), is an autosomal recessive CMD characterized by severe muscle weakness and degeneration apparent at birth or in the first 6 months of life. LAMA2 MD is the most common congenital muscular dystrophy, affecting approximately 4 in 500,000 children. The most common cause of death in early-onset LAMA2 MD is respiratory tract infection, with 30% of them dying within the first decade of life. LAMA2 MD is caused by loss-of-function mutations in the LAMA2 gene encoding for the laminin-α2 chain, one of the subunits of laminin-211. Laminin-211 is an extracellular matrix protein that functions to stabilize the basement membrane and muscle fibers during contraction. Since laminin-α2 is expressed in many tissue types including skeletal muscle, cardiac muscle, Schwann cells, and trophoblasts, patients with LAMA2 MD experience a multi-systemic clinical presentation depending on the extent of laminin-α2 chain deficiency. Cardiac manifestations are typically associated with a complete absence of laminin-α2; however, recent case reports highlight cardiac involvement in partial laminin-α2 chain deficiency. Laminin-211 is also expressed in the brain, and many patients have abnormalities on brain imaging; however, mental retardation and/or seizures are rarely seen. Currently, there is no cure for LAMA2 MD, but various therapies are being investigated in an effort to lessen the severity of LAMA2 MD. For example, antisense oligonucleotide-mediated exon skipping and CRISPR-Cas9 genome editing have efficiently restored the laminin-α2 chain in mouse models in vivo. This review consolidates information on the clinical presentation, genetic basis, pathology, and current treatment approaches for LAMA2 MD. Keywords: LAMA2, exon skipping, genome editing, non-homologous end joining, phosphorodiamidate morpholino oligomer, CRISPR/Cas9

Identification of LAMA2 Compound Heterozygous Variants: a Case Report

Limb Girdle Muscular Dystrophy 23 Caused by Compound Heterozygous Mutations of LAMA2 Gene

[Analysis of a child with congenital muscular dystrophy due to a novel variant of the LMNA gene]

Novel compound heterozygous mutations of LAMA2-limb–girdle muscular dystrophy: A case report and literature review

Missense mutations in LAMA2 causing a new phenotype of mild cognitive impairment, proximal myopathy, seizure, and severe leukoencephalopathy: A case report and protein analysis.

Clinical and Molecular Genetic Analysis of a Family with Late-Onset LAMA2-related Muscular Dystrophy

Detection of LAMA2 c.715C>G:p.R239G mutation in a newborn with raised creatine kinase: A case report

Identification of a LMNA (c.646c > T) Variant by Whole-Exome Sequencing in Combination with a Dilated Cardiomyopathy (DCM) Related Gene Filter in a Family with Familiar DCM

Compound heterozygous DYSF variants causing limb‐girdle muscular dystrophy type 2B in a Chinese family

P.8.6 Genotype/phenotype analysis in Chinese laminin-α2 deficient congenital muscular dystrophy patients

Unique Genotype-Phenotype Correlations Within LAMA2-related Limb Girdle Muscular Dystrophy in Chinese Patients

Identification of a Likely Pathogenic Structural Variation in the LAMA1 Gene by Bionano Optical Mapping.

Deletion of Exon 4 in LAMA2 is the Most Frequent Mutation in Chinese Patients with Laminin Α2-Related Muscular Dystrophy

Identification of Two Novel MYH3 Variants Causing Different Phenotypes in Prenatal Diagnosis.

Current understanding and treatment of cardiac and skeletal muscle pathology in laminin-α2 chain-deficient congenital muscular dystrophy

Case report and literature review: Novel compound heterozygous <i>FIG4</i> variants causing both of peripheral and central nervous system defects

Natural History and Genetic Study of LAMA2-related Muscular Dystrophy in a Large Chinese Cohort

Compound Heterozygous Variants of GOSR2 Associated With Congenital Muscular Dystrophy and Progressive Myoclonus Epilepsy: A Case Report

A Case Report of an Intermediate Phenotype Between Congenital Myasthenic Syndrome and D-2- and L-2-hydroxyglutaric Aciduria Due to Novel SLC25A1 Variants

Clinical Diagnosis and Genetic Analysis of Children With Muscular Dystrophies

Case report: A novel mutation of the CAPN3 gene in a Chinese family with limb-girdle muscular dystrophy type 2A